Carl Icahn Calls Pfizer/Allergan Deal a 'Travesty' - NY Times Op-Ed

The Pfizer (NYSE: PFE)/Allergan (NYSE: AGN) deal is a "travesty", Carl Icahn said in a New York Times Op-Ed piece:

"THE Pfizer-Allergan deal is a travesty. Pfizer, which is based in New York, will move overseas by merging with Allergan, based in Ireland, in a maneuver known as a corporate inversion. The point isn’t to find corporate synergy. It is to leave behind our uncompetitive international tax system.

Not only is this the largest inversion in history, but it will also open the floodgates for other companies to leave the United States, further eroding our tax base, damaging our economy and costing many thousands of jobs"

CONTINUE READING AT NY TIMES

You May Also Be Interested In

• Walmart expected to beat Q2 estimates as tariff refunds lift margins
• Activist investors push Seer, Inc. to disclose go-private timeline
• Lionsgate faces activist pressure to sell itself in ‘AI era’ - Semafor